[
    [
        {
            "time": "2019-09-06",
            "original_text": "Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs",
            "features": {
                "keywords": [
                    "AGN",
                    "Opioid",
                    "Settlement",
                    "Line Extension",
                    "EU",
                    "MRK",
                    "JNJ"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-09-06",
            "original_text": "Health Care Sector Update for 09/06/2019: NTGN, MYOV, VIVE, JNJ, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "NTGN",
                    "MYOV",
                    "VIVE",
                    "JNJ",
                    "PFE",
                    "ABT",
                    "MRK",
                    "AMGN"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 2,
                "Entity_Density": 10,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-09-06",
            "original_text": "Mallinckrodtâ€™s suffers record plunge after report bankruptcy is being considered",
            "features": {
                "keywords": [
                    "Mallinckrodt",
                    "record plunge",
                    "bankruptcy",
                    "considered"
                ],
                "sentiment_score": -0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-06",
            "original_text": "Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation",
            "features": {
                "keywords": [
                    "Mallinckrodt",
                    "Bankruptcy",
                    "Opioid",
                    "Litigation"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-09-06",
            "original_text": "How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks?",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Opioid",
                    "Case Ruling",
                    "Big Pharma",
                    "Stocks"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]